Almirall Arrives at Its 2028 Margin Two Years Early — and Stops Talking About 2026
A 25% EBITDA margin, guidance skewed to the top of the range, and a German rebate reform worth 1–2.5% of sales: the P&L is ahead of plan, but management went quiet on the one number analysts actually wanted.
ALM.MC · Earnings Call · 2026-11-09
The Margin Story Is Now the Whole Story
Almirall's nine-month update looked, at first pass, like a mid-cap specialty pharma hitting its marks: net sales of €889 million, up 8.3% year on year, a third quarter that accelerated to €286.5 million (+10.1%), and European dermatology compounding at 17.6% year to date as the clear growth engine. But the composition of the guidance is where the story sits. Full-year sales are now expected at the mid-to-low end of the 9–12% range; EBITDA is expected at the upper end, around €290 million against a €270–290 million band.
That is an unusual combination — a company trimming the top line while pushing the bottom line up — and it is the direct consequence of what has become Almirall's signature theme. “EBITDA for the first 9 months reached €222 million corresponding to a margin of around 25% of net sales, 2 years ahead of our 2028 ambition.” — Jon U. Garay Alonso, Executive or Senior Management (likely Commercial or Sales Head) · 2026-11-09 The operational leverage argument that management has been making for six straight quarters is no longer a promise; it has arrived, and the debate has shifted from can they get there to what do they do with it.
That matters because it strips out a valuation crutch and replaces it with a capital-allocation question — one Carlos Gallardo Piqué answers, as he has for a year, with licensing opportunities and bolt-ons, backed by financial flexibility that is now real rather than aspirational: free cash flow of €83 million versus €42 million a year ago, operating cash flow up 39%, net cash to EBITDA of roughly 0.2x, and a Moody's upgrade to Ba1 in June.
The German Hole Nobody Can Size Yet
Against that clean picture sits the single largest forward risk in the file. Germany's rebate reform, passed in July, is priced at 1–2.5% of group revenue for 2027 and beyond, per management's read of market estimates — and because it is a price mechanism, almost all of it should fall through to EBITDA. When an analyst asked precisely that, the CFO declined to quantify the margin path, pointing instead to the expense discipline and the raised EBITDA guide.
This is not a new concern; it is a three-month-old one that has stubbornly refused to resolve. On the July call, Carlos said the reform was “certainly not good news for the industry in Europe” — Carlos Gallardo Piqué · 2026-07-24 and that clarification would come by year-end. In November, the language had not advanced much at all:
There is still a lot of uncertainty About the impact of these reforms. Of course, we are monitoring it very closely, and we will provide an update once the negotiations conclude. Hopefully, in the next few weeks.
Worth noting: reform is a fresh mover in this quarter's keyword set, and the hedging around it — deductions, exemptions, eligibility — is the sort of thing that gets revisited on every call until it is nailed down. The stock's real 2027 risk is not demand for biologics; it is a German price line that management can bracket to a range but not yet to a margin.
The Question Management Stopped Answering
The more revealing moment came early. Asked about the current-year Ebglyss run-rate — consensus sits around €190–195 million — Gallardo answered entirely about the long term: “We are happy to reiterate our peak sales estimate of more than €450 million.” — Carlos Gallardo Piqué · 2026-11-09 The analyst had to come back and ask again, explicitly, for the 2026 figure. She did not get one.
That is a change in behaviour, not in the underlying business. Three months ago the CFO answered the same question directly: “The market consensus for the products shown at this point in time is in the range of EUR 190 million to EUR 193 million, and we remain comfortable in this ballpark for this year.” — Jon U. Alonso, CFO · 2026-07-24 The shift from "comfortable with the ballpark" to "here is our peak sales number" is a tell about the fourth quarter, and analysts read it. Hence the meta-question from CaixaBank's Guilherme Sampaio, which is the sharpest line on the call: “over the short term, you used to be a bit more reassuring than you were today.” — Guilherme Sampaio, Analyst · 2026-11-09 The reply — “I said what I said before” — Carlos Gallardo Piqué · 2026-11-09 — confirms intent rather than deflecting an accident.
The atopic dermatitis franchise still carries the narrative; AD touch and the five-year ADlong durability data were the scientific highlights of EADV, and Ebglyss still grew 75% to €132 million. But there is a difference between a franchise whose long-term clinical profile is being reinforced and a franchise whose next quarter management will not characterise. Minor gross-margin drift points the same way — the CFO flagged that the 65% gross margin is not a proxy and something near 64% is closer, as royalty-bearing biologics take a larger share of the mix.
The Readout Wall Starts Now
Where the optimism is genuinely earned is the pipeline, and it is about to stop being theoretical. Almirall has six proof-of-concept or Phase 2 programmes, with the first readout — the IL-2 mutant Fc in atopic dermatitis — expected this quarter, and the remainder through 2027 and early 2028. The anti IL-1RAP antibody now runs in Hidradenitis suppurativa and is being extended into pyoderma gangrenosum; an anti-IL-21 sits alongside it in HS.
The HS thesis has been repeated for over a year, including the market sizing, and Karl Ziegelbauer's framing has barely changed since 2025 — “which is, from the prevalence, about ¼ of AD” — Karl Ziegelbauer, R&D or Pipeline Executive · 2025-05-12 — which is fine, but it means the readouts, not the rhetoric, are the event. What is newer is the sourcing model: activities in China and the Cristal ion-channel collaboration, where Almirall buys optionality on molecules and keeps global rights rather than paying for infrastructure.
What Actually Changed
One number moved decisively: the margin target is now a margin fact, two years early. Everything else moved sideways-to-better — Ilumetri's best-ever quarter at €65 million with 11.5% growth year to date, Ebglyss still compounding in the seventies, cash conversion roughly doubling. The legacy portfolio remains a slight drag and, by management's own framing, likely to stabilise rather than recover.
The tension worth watching is this: a company guiding sales to the low end while guiding profit to the high end, facing a price reform it can bracket but not yet quantify, and declining to characterise the near-term trajectory of its fastest-growing product. That is a management team confident in 2028 and noticeably less willing to be pinned down on 2026 — and the market now has six clinical readouts and one German negotiation to price before that confidence gets tested.